Surveys among pharmacists and physicians show that these healthcare professionals have successfully adopted the concept of pharmacogenomics (PGx).1-3 In addition, patients are willing to consent to participate in PGx implementation studies.4 However, the surveys also show that healthcare professionals do not frequently order or recommend a PGx test.1,2 Among others, a frequently perceived hurdle for clinical uptake of PGx is the availability of guidelines translating PGx test results into clinical actions for individual patients.5,6.

Additional Metadata
Persistent URL,
Journal Clinical Pharmacology and Therapeutics
Grant This work was funded by the European Commission 7th Framework Programme; grant id h2020/668353 - Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen (U-PGx)
Swen, J.J, Nijenhuis, M, van Rhenen, M. (Mandy), de Boer-Veger, N.J. (Nienke J.), Buunk, A.-M. (Anne-Marie), Houwink, E.J.F. (Elisa J.F.), … Guchelaar, H.J. (2018). Pharmacogenetic Information in Clinical Guidelines: The European Perspective. Clinical Pharmacology and Therapeutics (Vol. 103, pp. 795–801). doi:10.1002/cpt.1049